Stock Movers

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:
- Constellation Energy (CEG) shares fell as much as 9.3% after it gave an full-year earnings per share guidance that missed the average analyst estimate at the midpoint, and failed to advance details on data-center deals.

- Marvell Technology (MRVL) shares jumped as much as 11% in trading on Tuesday on news that Nvidia (NVDA) is taking a $2 billion stake in it. Nvidia, which has made several billion-dollar investments in firms across the artificial intelligence supply chain in recent years, and Marvell also agreed to collaborate on the development of silicon photonics, which use light instead of traditional copper wiring to move data faster and more efficiently. And the companies will work together on ways to better leverage telecommunications networks for AI computing, according to a statement issued Tuesday.

- Unilever (ULVR) shares fall as much as 7.3% in London to the lowest level since April 2024 after the Anglo-Dutch company confirmed a $44.8 billion deal to combine its food business with spice maker McCormick. Analysts at RBC Capital Markets said they are unimpressed by the deal. McCormick shares fell as much as 10% to the lowest since November 2017.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

- Constellation Energy (CEG) shares fall after it gave an full-year earnings per share guidance that missed the average analyst estimate at the midpoint.

- McCormick (MKC) shares decline. Unilever Plc agreed to combine its food business with McCormick & Co. in a $44.8 billion deal that will create a global seasonings, sauces and condiments company. Under the agreement, McCormick will pay Unilever $15.7 billion and the equivalent of $29.1 billion McCormick shares for most of Unilever’s food business, leaving Unilever and its shareholders with 65% of the combined entity.

- Apellis Pharmaceuticals (APLS) shares gain after Biogen agreed to acquire Apellis for $5.6 billion, expanding its treatments in immunology and rare diseases. The acquisition will give Biogen two approved drugs, Syfovre and Empaveli, which treat immune disorders and rare diseases, including a leading cause of blindness and rare kidney diseases.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

- Eli Lilly (LLY) shares gained. The company agreed to buy sleep drug maker Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, a sign the weight-loss medication giant is looking to bulk up its treatment pipeline for other conditions.

- McCormick (MKC) shares rise. Unilever Plc agreed to combine its food business with spice maker McCormick & Co. in a $44.8 billion deal that will create a global seasonings, sauces and condiments company. Under the agreement, McCormick will pay the Anglo-Dutch company $15.7 billion and the equivalent of $29.1 billion McCormick shares for most of Unilever’s food business.

- Allbirds (BIRD) shares soar. American Exchange Group has agreed to buy all of the assets and intellectual property of once-buzzy footwear brand Allbirds Inc. for $39 million. The shoemaker said the deal, which is expected to close in the second quarter, still needs shareholder approval. A distribution of net proceeds to stockholders is expected in the third quarter.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.

On this episode of Stock Movers:

- Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year.

- Eli Lilly (LLY) agreed to buy sleep drug maker Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, a sign the weight-loss medication giant is looking to bulk up its treatment pipeline for other conditions.
Lilly will pay $38 a share for Centessa plus a further $9 a share if three milestone targets are met, according to a statement Tuesday. The total represents a 70% premium to Monday’s close. The upfront payment represents an equity value of about $6.3 billion, with potential additional payments of about $1.5 billion.

- Nvidia (NVDA) said it has invested $2 billion in Marvell Technology (MRVL) as part of an agreement to collaborate on silicon photonics technology, an effort to make AI services more affordable amid historic investments in the new technology.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Lilly (LLY) to buy Centessa Pharmaceuticals for $38/share in cash plus one non-transferrable contingent value right that entitles the holder to get up to an aggregate of $9 subject to the achievement of three milestones.
- Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year.
- Unilever (ULVR) said talks to sell most of its food business to McCormick (MKC) are advanced and a final deal could be announced later on Tuesday in a historic move that will transform both companies.The Anglo-Dutch maker of Hellmann’s mayonnaise will offload most of its food unit, excluding some parts like its operations in India, for $15.7 billion cash upfront and the rest in McCormick equity, according to a statement Tuesday.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- LVMH, SAP, and Novo Nordisk have slumped by about 30% so far this year, making up about 53% of the total market capitalization shed by constituents of the Stoxx Europe 600 index.
- Future slumps as much as 30%, to the lowest since October 2017, after what JPMorgan describes as a weak first-half trading update, showing impact from pressure on high-margin programmatic advertising and e-commerce revenue, and pay-per-click cost inflation.
- Dermapharm shares fall 4.8% after the company announced full year results. Dermapharm forecast adjusted Ebitda for 2026 of EU331 million to EU341 million.

See omnystudio.com/listener for privacy information.

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- LVMH, SAP, and Novo Nordisk have slumped by about 30% so far this year, making up about 53% of the total market capitalization shed by constituents of the Stoxx Europe 600 index.
- Future slumps as much as 30%, to the lowest since October 2017, after what JPMorgan describes as a weak first-half trading update, showing impact from pressure on high-margin programmatic advertising and e-commerce revenue, and pay-per-click cost inflation.
- Mundys is close to unveiling a plan to increase its stake in Channel Tunnel operator Getlink SE, people with knowledge of the matter said, in a move aimed at deepening the Italian infrastructure group’s investments in France. Shares in Getlink have risen 12.5% over the last 12 months, giving the company a market value of about €9.9 billion ($11.3 billion).

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:
- Shares of security software companies are rising on Monday, with the group rebounding in the wake of recent weakness, which had been spurred by concerns over AI-related disruption. The Global X Cybersecurity ETF rose 2.4%. Palo Alto Networks shares were leading the S&P 500 higher on Monday, while shares of fellow cybersecurity companies were seeing strong rallies as well. A few factors may help explain the big moves.

- Sysco (SYY) shares sink as much as 14%, the most intraday since April 2020, after the food and related products distributor agreed to acquire Jetro Restaurant Depot for $21.6 billion in cash and 91.5 million Sysco shares.

- Shares of Fannie Mae (FNMA) and Freddie Mac (FMCC) surged by more than 30% each on Monday after Bill Ackman called both stocks “stupidly cheap,” the billionaire’s latest bullish bet on the U.S.-controlled mortgage giants he’s lobbied to have relisted on the public markets, as the Trump administration considers plans.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Bailey Lipshultz, Katie Greifeld, Carol Massar and Tim Stenovec.

- Boston Scientific (BSX) shares tumble as much as 11%, the most intraday since February 4, after results from the medical device maker’s trial of the Watchman heart implant fell short of investor expectations. Leerink Partners says the data is “not the home-run scenario” that bulls wanted.

- Alcoa (AA), Century Aluminum (CENX), and other mining stocks were jumping on Monday, after Iran targeted two major Middle Eastern aluminum producers over the weekend.Alcoa was up 10% to $64.31 in midday trading. Century Aluminum, jumped 7.7%, while Kaiser Aluminum was up 1.5%.

- Shares of Fannie Mae (FNMA) and Freddie Mac (FMCC) surged by more than 30% each on Monday after Bill Ackman called both stocks “stupidly cheap,” the billionaire’s latest bullish bet on the U.S.-controlled mortgage giants he’s lobbied to have relisted on the public markets, as the Trump administration considers plans.

See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:

- Boston Scientific (BSX) shares tumble as much as 11%, the most intraday since February 4, after results from the medical device maker’s trial of the Watchman heart implant fell short of investor expectations. Leerink Partners says the data is “not the home-run scenario” that bulls wanted.

- Sysco (SYY) shares sink as much as 14%, the most intraday since April 2020, after the food and related products distributor agreed to acquire Jetro Restaurant Depot for $21.6 billion in cash and 91.5 million Sysco shares.

- Shares of Fannie Mae (FNMA) and Freddie Mac (FMCC) surged by more than 30% each on Monday after Bill Ackman called both stocks “stupidly cheap,” the billionaire’s latest bullish bet on the U.S.-controlled mortgage giants he’s lobbied to have relisted on the public markets, as the Trump administration considers plans.

See omnystudio.com/listener for privacy information.